A Nrf2-OSGIN1&2-HSP70 axis mediates cigarette smoke-induced endothelial detachment: implications for plaque erosion.

"Conflict of interest: None of the authors have received any financial, personal, or professional support, other than the funding disclosed above that has a bearing on the data presented here. Dr Libby is an unpaid consultant to or involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron. Dr Libby is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, TenSixteen Bio, and XBiotech, Inc.: Dr Libby’s laboratory has received research funding in the last 2 years from Novartis. Dr Libby is on the Board of Directors of XBiotech, Inc. Dr Libby has a financial interest in XBiotech, a company developing therapeutic human antibodies. Dr Libby has a financial interest in TenSixteen Bio, a company targeting somatic mosaicism and clonal haematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. Dr Libby’s interests were reviewed and managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies."

"Funding The work was supported by British Heart Foundation (grants: PG/11/44/28972, FS/12/77/29887, CH95/001, PG/17/67/33218), internal strategic funding from Manchester Metropolitan University, the National Health Research Institute (UK) Bristol Biomedical Research Unit in Cardiovascular Medicine and the European Commission through MOVE-AGE, an Erasmus Mundus Joint Doctorate program (2011-0015), the US National Heart, Lung, and Blood Institute (R01HL134892 and R01HL163099), the American Heart Association (18CSA34080399), the RRM Charitable Fund, and the Simard Fund."